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A B S T R A C T
In this era of information technology, big data analysis is entering biomedical sciences. But what is big data,
where do they come from and what can we do with it? In this commentary, the main sources of big data are
explained, especially in (head and neck) oncology. It also touches upon the need to integrate various sources of
clinical, pathological and quality-of-life data. It discusses some initiatives in linking of such datasets on a nation-
wide scale in the Netherlands. Finally, it touches upon important issues regarding governance, FAIRness of data
and the need to bring into place the necessary infrastructures needed to fully exploit the full potential of big data
sets in head and neck cancer.
Introduction
Big data and the computer technology to analyze it are called one of
the top 10 revolutions in the coming decade [1]. It is foreseen that its
impact parallels that of the Internet, the cloud, and, more recently,
block-chains (known from crypto-currencies as the bitcoin) [2]. Big
data phenomena are penetrating in virtually all sectors. On large scale,
they have been ﬁrst applied by information power companies (IBM,
Google, Facebook, Amazon). Algorithms, using neural networks and
machine-learning techniques have been developed and are used by
these large IT-oriented companies to predict behavior of people and use
this information for person-oriented marketing. Also health insurance
companies and governments have large interest in big data develop-
ments and big data have entered life sciences too. But what is big data
and what can we do with it? [3].
Deﬁnition of big data
Though many people and companies use the word “big data”, they
may not always mean the same, or interpret it in the same way. Most of
us have a vague notion of what it could be (“anything that won’t ﬁt an
excel sheet”), but big data is not just synonymous to “a lot of data”. A
way to deﬁne big data in health care, is its description according to the
5 V’s (https://www.ibm.com/blogs/watson-health/the-5-vs-of-big-data
The 5 Vs of Big data, September 17, 2016 Anil Jain). From this deﬁ-
nition, big data contain:
- Volume: big data are of big size, containing a lot of data points/
records of multiple subjects. These include diagnostic work-up
[clinical, radiological, pathological), treatment data (surgery, sys-
temic therapy, radiotherapy and their combinations), response data
and complications.
- Velocity: big data has two velocity aspects: [1] big data are created
at an increasingly high speed, and [2] they have to be computed/
digested relatively fast. Worldwide the incidence of cancer is in-
creasing, while patients live longer. Together with the technological
advances and monitoring devices, an increasing number of data will
have to be processed within the same time.
- Variety: big data comprise a huge variability of data types. This
variety has important opportunities (many diﬀerent data types en-
rich the quality and usefulness of it), and challenges regarding its
heterogeneity warranting standardization (synoptic reporting).
- Variability: it’s crucial to realize that data capturing varies in place
and time. Capturing a (predeﬁned) mandatory minimal dataset is a
prerequisite to get most of (synoptic) reported data. This doesn’t
only need consensus on the minimal data required; it also involves
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univocal deﬁnitions (e.g. recurrence vs residual disease).
- Value: setting up a data infrastructure to collect and interpret data is
only worthwhile, when it enables generation of data-derived con-
clusions or measurements based on accurate data that can really
lead to measurable improvements or impact in health care.
While the sheer size of data collections is often an issue, an even
more pressing problem is that data resources are typically spatially
distributed across the globe and deposited in ways that make it diﬃcult
to integrate the data. This may lead to scalability problems since the
data need to be transported via the internet, but, more importantly,
requires harmonization and standardization eﬀorts if the data is to be
integrated and used in a common workﬂow to answer an overarching
query.
Why do we want big Data?
Big data are practical useful in various areas. Location tracking
helps logistic companies to mitigate risks in transport, speed and re-
liability of delivery. In the ﬁnancial world, Securities Exchange
Commission (SEC) uses big data network analytics to identify possible
frauds. Entertainment companies such as Netﬂix and YouTube use past
views and online behavior to increase engagement and drive more
revenues. Advertising companies are probably the biggest big data
players. Data analyzed from Facebook, Twitter and Google monitor
behavior and transactions that advertisers use to run targeted cam-
paigns. Breeding companies use drones ﬂying over the crop ﬁelds,
sending back imaging data to inform the breeding process. With big
data, hospitals can improve monitoring of intensive care patients.
Eﬃciency of (expensive) medication can be measured and epidemic
outbreaks can be forecasted in an early stage.
More speciﬁcally for the medical disciplines, big data could be
helpful in developing and reshaping disease prevention strategies.
Combining large data sets of genomics and environmental data will
help to predict which individuals/groups are at risk for developing
certain (chronic) diseases and cancer. This might elicit speciﬁc actions
aimed to inﬂuence the environmental factors and behavior that con-
tribute to health risks in target groups. Big data will also be helpful to
evaluate current prevention programs and might help to identify novel
insights to improve these. Also in a therapeutic setting, big data are
instrumental to monitor e.g. the eﬀects of speciﬁc therapies, such as
those of expensive oncolytics, especially in relation to patient and
tumor (genetic) characteristics. This will help to improve precision
medicine and fuel important knowledge to calculate cost-eﬃciency of
certain treatment regiments.
Data sources of Big Data in Medicine
Sources for big data are plentiful and can be of diﬀerent kinds. In
oncology, the most obvious are patient derived data. These include
various data points/subject and are usually recorded in electronic
patient ﬁles for clinical purposes. These data contain the clinical data of
patients, tumors, treatment and outcome and may include demographic
details such as gender and age, presenting symptoms, family history,
comorbidity, radiological data (such as CT, MRI, PET, US) as well as
solid and liquid tissue-based analysis (such as histopathological diag-
nosis/features, immunohistochemistry, DNA/RNA sequencing experi-
ments, blood analyses and whole genome BAM ﬁles which contains on
average ~ 100 GB). But also data from in vitro experiments are im-
portant and can be an important source. A second source of big data
includes the computational analysis of these data. These processed data
comprise indirect and computed data, including radiomics and digital
image analysis as well as genetic expression and mutation analyses. An
increasing source of these processed data come from machine learning
and usually contains large computer data ﬁles of structured data.
A third source of big data comes from the patients themselves, in-
cluding patient related outcome measurements (PROMs) and patient
related experience measurements (PREMs) who record all kinds of
measures using apps on computers and mobile devices, either provided
by their caregivers (eHealth, telemedicine) or by their own initiative.
A fourth source is from published literature (IBM project). As every
year over 1M biomedical articles are published, there is no doctor in
the world who can read even just a fraction of the knowledge published,
let alone all relevant textbooks and other internet sources.
Nevertheless, one key factor stands out for big data in oncology: the
depth (volume) of data per patient. In oncology many observables
(thousands to even millions) per patient are routinely generated and
stored, while typical cohort sizes of patients are relatively small. This
imbalance in the depth of data per patient versus the cohort size is even
more prominent for rare cancer types such as head and neck cancer.
However, recent methodological advances in machine learning and
neural network are speciﬁcally powerful if there are instances to learn
over. For example, object recognition in images works very well, but
thousands to millions of examples are needed to optimize such
methods. Hence, if we want to translate this to optimize personalized
treatments, we also need data depth in the number of samples [4]. This
makes good data keeping, data standardization, data sharing, data
provenance and data exchange protocols essential for oncology, and
absolutely necessary in the ﬁeld of head and neck oncology.
Integration of big data in head and neck cancer (HNC)
So as sources are multiple and volumes are high, standardization in
data capturing is warranted. This standardization will lead to much
more uniform and complete datasets, which are easier to link to other
data resources. Standardization is essential for data integration, which
is needed for data interpretation and creating value from the data. E.g.
to monitor the quality of care after speciﬁc surgical interventions, it’s
crucial to understand the case mix of patients in terms of tumor stage,
(neo) adjuvant therapies, co-morbidity, etc.
In The Netherlands, several national databases have been estab-
lished to structurally capture clinical, pathological, genetic/genomic
Table 1
Data sources for most common cancer types in The Netherlands, including HNC.
Tumortype Clinical Pathological Genetic/genomic Radiological PROM/PREM
HNSCC DHNA PALGA PALGA/HMF NET-QUIBIC
breast cancer NBCA PALGA PALGA/HMF
lung cancer DLCA/NVALT PALGA PALGA/HMF
prostate cancer PALGA PALGA/HMF
CRC DSCA PALGA PALGA/HMF
melanoma DMTR PALGA PALGA/HMF
For most common tumor types, collections of various data (clinical, pathological genomic/genetic) have been well organized, with the exception of radiological data.
DHNA: Dutch Head and Neck Audit; NBCA: National Breast Cancer Audit; DLCA: Dutch Lung Cancer Audit.
DSCA: Dutch Surgical Colorectal Audit; DMTR: Dutch Melanoma Treatment Registry; PALGA: Pathologisch Anatomisch Landelijk Gegevens Archief; HMF: Hartwig
Medical Foundation.
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data and PROM/PREMs (Table 1). Clinical data are being reported since
2014 in the Dutch Head and Neck Audit (DHNA), which was in-
corporated in the Dutch Institute for Clinical Auditing (DICA) 2017 who
installed subgroups for speciﬁc disease types (cancer and non-cancer).
Tumor tissue based data such as pathological and genomic/genetic data
have been structurally collected nation-wide, and now also synoptically
reported for> 20 diﬀerent tumor types. In contrast, structured data
basing of radiological data is still lacking. In addition to other cancer
types, for head and neck, the NET-QUBIC consortium has initiated the
national platform to report PREMs/PROMs for HNC. So for HNC in The
Netherlands, most patient-derived data sources have now been in-
stalled. Internationally, many similar initiatives are underway, e.g. the
head and neck squamous cell carcinoma (HNSCC) collection [5] and
The Cancer Imaging Archive (TCIA) [6]. The essential next step is to
bring these data together now, preferentially on the individual patient-
level.
In the Netherlands, head and neck cancer care is centralized in 8
head and neck centers with 6 preferred partners and united within the
Dutch Head and Neck Society (NWHHT). This places the head and neck
cancer community in the ideal position to unite the expertise and en-
deavors to optimize uniform data input and roll out of the current se-
parate databases. Moreover, head and neck cancer is in the ideal po-
sition to establish nationwide linkage of these databases and develop
algorithms for integrated data-analysis.
Utility of big data
The future potential of big data (in biomedical research) is not fully
clear yet. For today (and tomorrow), big data will create value for [1]
daily diagnostics, [2] quality of care/life (including PROMs and
PREMs) and [3] biomedical research [7]. We will give some examples
of currently available applications.
Daily diagnostics
Big data can already have relevance in every day clinical practice.
An example is the near-real time access Dutch pathologists have to the
nationwide histopathological follow up of each individual patient. The
PALGA foundation governs all digital histopathological records in The
Netherlands ever since 1971 (www.palga.nl). Containing over 72 mil-
lion records of over 12 million patients in The Netherlands, PALGA is
one of the largest biomedical databases in the world and covers all 55
pathology labs in The Netherlands. Every time a Dutch pathologist
authorizes a histopathology report, one copy is stored in the local
hospital information system, and one copy in the central PALGA data-
base. So, this database contains real time pathological follow up of each
patient that is directly visible for each PALGA member (pathologist or
molecular biologist). This oﬀers huge potential in recognizing relevant
patient (oncological) history, e.g. ruling out a recent malignancy in
cases of a suspect tumor of unknown primary; or oﬀering pathological
documentation on previous relevant pathological features (such as re-
section margins and positive lymph node) in case pathology was per-
formed in another lab. Also co-occurrence of diseases or unknown as-
sociations in low prevalent disease, that at ﬁrst sight seem not to be
related can be studied using this database [8].
Electronic patient ﬁles generate an enormous amount of medical
data, which can be used for prognostic modeling. One of the ﬁrst
prognostic models for HNC patients receiving care at medical centers in
developed countries is available online at www.oncologiq.nl [9]. Au-
tomatization of statistical prognostication processes allows automatic
updating of models when new data is gathered [10]. These data can
also be used to develop clinical decision making tools for improved
patient counseling and non-binary patient related outcome measure-
ments.
Quality of care measurements
Linking databases on patient outcomes with data on patient char-
acteristics and treatment can oﬀer unprecedented potential for feeding
back quality an eﬃcacy of care. Recently, a French study showed the
landscape of molecular testing for targeted therapy in non-small cell
lung cancer (NSCLC) in France and subsequent treatment regiments
based on this [11]. This allows direct feedback on optimal test-treat-
ment correlations. More importantly, it might be a strong incentive for
underperforming labs, to revise their protocol/workﬂow to improve
their optimum of care. Also in The Netherlands, linking data from the
national cancer registry (containing clinical stage, treatment and out-
come data) with the aforementioned PALGA database, has been able
the show the variety in clinical care in head and neck cancer in The
Netherlands [12,13]. Though improving the quality of care can only be
reached by transparency on such data, it should be realized that feed-
back of such data, especially outcome data and when benchmarked, can
only be done with indisputable prudency as labs and hospitals might
fear reputation damage or naming-and-shaming [14]. In practice, when
published anonymously to the public and fed back disclosed only on the
individual level, experience learns that most hospitals are actually
happy to cooperate in such mirror feedback. This has led in The
Netherlands to the development of algorithms for automatic feedback
of pathology and treatment related items on a regular basis, such as the
Dutch Institute for Clinical Auditing (www.dica.nl). Mirror information
showing higher recurrence rates than those in peer hospitals, possible
will be an incentive to zoom in on the underlying chain to identify (and
solve) potential weaknesses.
Biomedical research
Probably most beneﬁt will be generated from big data in the ﬁeld of
research. The leading era of “genome wide association studies” (GWAS)
has been broadening towards an era of “data wide association studies”
(DWAS), with a central place for big data. Increase of data, both due to
increased used of imaging and molecular analyses and combinations
with other data, oﬀer a matchless Walhalla for each data scientist and
bioinformatician. Big data ﬁll an unmet need in biomedical research.
For example, an important limitation of today’s medicine is our poor
understanding of the biology of disease. Only by aggregating huge
amounts of big data, all relevant multisource variables, such as DNA,
RNA, protein and metabolomics data will aggregate and can be in-
tegrated in more realistic models to predict how tumors will behave and
which patients will beneﬁt best form speciﬁc therapies. These in-
tegrated multi-omics data will for example provide more comprehen-
sive insight into biological behavior and mechanisms that underlie
growth patter, metastatic potential as well as response to (targeted)
treatment of HNSCC.
Personalized medicine
From the perspective of turning our current understanding and
available data into actionable insights that can be used to improve
treatment outcome, personalized medicine is absolutely dependent on
big data [15]. The amount of data available for the biomedical com-
munity exponentially increases, especially with advancing technologies
generating terabytes of data, notably in sequencing and imaging. In
terms of quantity, most data do not come from direct, patient related
records available from daily clinical practice, but to a larger extent from
computed automatic data analyses such as radiomics and digital image
analysis. Head and neck cancers present a unique set of diagnostic and
therapeutic challenges by nature of its complex anatomy and hetero-
geneity. Radiomics holds the potential to address these barriers [16].
Radiomics extracts and mines a large number of medical imaging fea-
tures in a non-invasive and cost-eﬀective way. The underlying as-
sumption of radiomics is that these imaging features quantify
S.M. Willems, et al. Oral Oncology 98 (2019) 8–12
10
phenotypic characteristics of an entire tumor. Radiomics in precision
oncology and cancer care allow for prognostic and reliable machine-
learning methods for the stratiﬁcation (or personalization), i.e. identi-
fying diﬀerences in (expected/predicted) survival between (groups of)
patients, and prediction of treatment outcome(s) to support selection of
the best possible treatment of head and neck cancer patients [17]. This
might enable medical and radiation oncologist to (de-)escalate systemic
treatment and irradiation doses in speciﬁc patient populations.
FAIR data
To ensure data can be reused in secondary studies, it is essential
they adhere to the FAIR (Findable, Accessible, Interoperable, Reusable)
principles. These FAIR data principles have been ﬁrst published in 2014
[18]. Since then, the principles have been recognized and endorsed by
the G20 (2016) and the G7 (2017), while the EU has taken FAIR data at
the heart of the European Open Science Cloud (EOSC). An important
part of FAIRness of a data resource is concerned with its metadata,
where ﬁndability (F) is reliant on having a persistent identiﬁer in place;
accessibility (A) requires clearly deﬁned access rules (data privacy
constraints are within the deﬁnition) and licensing; and interoperability
(I) is dependent upon employing a community-recognized ontology for
describing the data. Finally, provenance of the data and accurateness
and completeness of the meta-data is essential for the reusability (R) of
the data.
Challenges and future perspectives
Though already applied in current clinical practice, and with tre-
mendous promises ahead, producers of big data also face challenges to
make them optimally useful in life sciences. First of all, with rapidly
developing technologies, such as next generation sequencing (espe-
cially whole exome/genome sequencing) and radiomics, the volume of
data continues to increase exponentially. These huge amounts of data
add an increasing complexity that might impede data interpretation.
This holds especially true when the increase in data (velocity and vo-
lume) is also paralleled by an increase in the heterogeneity of data
(variability), including treatments, outcomes, diﬀerences in study de-
sign, analytical methods and interpretation pipelines, which hamper
drawing ﬁrm conclusions from the data.
A second challenge comes with the proper governance of data,
especially when linked from various sources. How and which data are
made available, who is the owner of the data? Does the patient still
have governance of this own datasets? Or does the researcher governs
it, and if so, which researcher, or the treating physician, the data
generator, or is it the person who tries to make sense out of the data
(e.g. the computational biologist or medical bioinformatician)?
Repositories and databases for archiving and sharing
biomolecular patient data
In a (bio)medical research setting, the aim is often to obtain as many
data as possible from as many patients and hospitals as possible, while
privacy issues as well as security and protection measures (GDPR) often
prohibit the availability.
One key challenge is to store patient identiﬁable data, such as
genome sequences, in such a way that the data can be reused for other
studies, while safe guarding the privacy of the patients from which the
data was collected (www.phgfoundation.org). Whereas for large data
sets in other domains, such as computer science, open accessibility may
be preferred, here privacy concerns must clearly outweigh a desire for
complete openness. The European Genome Archive (EGA) is a purpose-
built database to store raw sequencing data. For each study, with data
stored in EGA, there is a strong role for a data access committee (DAC),
which is governed by the research initiative that collected the data and
can decide to provide access to the data upon request by other
researcher [19]. A secondary challenge is posed, when researcher
would like to browse processed biomolecular data, without the ability
to trace back individual markers. Here several solution are available
that summarise the data without showing individual markers [20], or
other repositories solve this by ﬁne graining access control [21]. Lastly,
a remaining challenge is to link the diﬀerent data resources in a privacy
aware manner, while being able to track the exact computational pro-
cessing that has been performed on the data; several initiatives have
made the ﬁrst steps to achieve such linking [22,23,4].
The potential use of big data in life sciences and head and neck
oncology is tremendous. It might also transform the way we share
clinical and research data. Instead of individuals or organizations
physically sharing datasets, the (near) real time/streaming of data to-
gether with the huge volume of data, will make it impossible to keep
exchanging data sets like we do today. Instead of bringing together all
kind of datasets in a central comprehensive database, a likely scenario
might be that big data users will develop more organic, decentralized
virtual networks, such as envisioned in the personal health train by the
Dutch Techcentre for Life Sciences (DTL) [24]. Within these networks,
databases are connected as nodes, accessible under predeﬁned condi-
tions to users. Increased connectivity and (thus) complexity will also
demand new ways of interpreting data, as well as translating these data
and its interpretations back to the individual patient. This latter re-
quires big data-derived knowledge computed from all these data sets to
be translated to the speciﬁc “small data” environment of the individual
care dependent patient. For this last step, crucially also integrating
intuitive and emotional aspects, we still need medical professionals.
Bed side manners are for the foreseeable future well out of reach of big
data or machine learning approaches.
Conclusion
The value of big data capturing relies on the volume, velocity
variety, veracity of various, often complex, data sets. Integration of
these sources is key and will be beneﬁcial for improvements in bio-
medical research, patient care and monitoring quality of care. In The
Netherlands, where head and neck cancer care is centralized and var-
ious national big data resources are in place, there is an unique op-
portunity to unite, link and integrate these data and fulﬁll this unmet
need. Such a head and neck cancer infrastructure should optimize data
input as well as (bioinformatical) data integration including
FAIRiﬁcation.
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